Advaxis — Investor Presentation (February 2019)
30 slides from Advaxis's investor presentation, Feb 7, 2019
Slide 1: Innovations in Immuno-Oncology: Corporate Presentation
“ Innovations in Immuno-Oncology S = .f ‘ _ ADVAXIS Corporate Presentation February 2019 Nasdaq: ADXS
Slide 2: Forward-Looking Statements
Forward-Looking Statements De velaiee This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and strategies of Advaxis, Inc. (the “Company”) to develop and commercialize cancer immunotherapies, timing of planned clinical trials and regu
Slide 3: Advaxis Overview
Advaxis Overview Creating Next-Generation Cancer Immunotherapies, Using a Proprietary Lm Platform Unique Lm Technology Platform: Enables broad and diverse pipeline of Phase 1 to Phase 3 programs across several tumor types Platform Validation: Demonstrated manageable safety profile along with clinica
Slide 4: Clinical Pipeline Overview
Clinical Pipeline Overview ADVAXIS een | | ms | roses | races | ADXS-HPV AIM2CERV, High-Risk, Locally Advanced Cervical’ (AXAL) HPV+ Head and Neck (Partners to be announced) LSS *& a1 2019 Metastatic Prostate in Combination ADXS-PSA with KEYTRUDA® (pembrolizumab) Cx) MERCK a Multiple Cancers by Targ
Slide 5: Our Differentiator: Lm Technology Platform
ADVAXIS IMMUNOTHERAPIES™ Our Differentiator: Lm Technology™ Platform << s+
Slide 6: How Our Lm Platform is Designed
How Our Lm Platform is Designed Lm vectors: Mimic natural infection and redirect immune response against cancer through: 1. INNATE IMMUNITY: Enhanced antigen presentation activates multiple pathways and alerts and trains the immune system 2. ADAPTIVE IMMUNITY: Mobilizes and generates a cancer-specif
Slide 7: AIM2CERV Phase 3 trial in high-risk, locally advanced cervical cancer
IMMUNOTHERAPIES™ Bethe! AIM2CERV -— Phase 3 clinical triatin 0 on high-risk, locally advanced cervical a cancer a? ’
Slide 8: Cervical cancer: Statistics and Unmet Need
Cervical cancer: Statistics and Unmet Need roe aes Cervical cancer 5-year survival rate, by disease stage Precancerous 98% @ Anestimated 91% of all cervical cancers or 93% are caused by an HPV infection 1A 93% @ While the overall incidence rate is expected to remain relatively stable, the IB 80% num
Slide 9: Annual, Worldwide Peak Revenue Opportunity of $500M for AXAL
Annual, Worldwide Peak Revenue Opportunity of $500M for AXAL in High-Risk Locally Advanced Cervical Cancer. IMMUNOTHERAPIES Market Opportunity in the U.S and Europe - Estimated Annual Revenues $210M Combined Worldwide Estimated Market Opportunity of ~$500M * Source: December 2016, LEK AXAL Assessmen
Slide 10: Supportive Clinical Trials
Supportive Clinical Trials Phase 2 Study in India: Prolonged Survival and Tumor Response in Randomized, Multicenter Phase 2 Study in Recurrent/ Refractory CC Illustrated the Promise of Lm Technology’ ¥ 34.9% 12-month survival rate (38/109), 24.8% (27/109) 18-month survival rate, 3 confirmed CRs obse
Slide 11: Additional Supportive Clinical Trials
Additional Supportive Clinical Trials AXAL Phase 1/2 BrUOG Study — High Risk Advanced Anal Cancer Isis WeeaienAEIE Commentary ( * 11 total patients enrolled Chills/Rigors 4 (40) 2 (20) ° All patients who completed RT and TANS 11 ate received treatment achieved a CR at TIN) 10 TS mee), 1 (10) 0 six m
Slide 12: ADXS31-164 Phase I - Survival Data from Canine Osteosarcoma Study
ADXS31-164 Phase | - Survival Data from Canine Osteosarcoma Study with ADXS-HER2 ADXS31-164 prolongs OS in HER2* OSA e This trial compared SOC amputation and chemotherapy 106 (in case matched controls) to SOC followed by 3 doses of a ADXS31-164 (ADXS-HER2) e These data show a highly significant impr
Slide 13: Axalimogene Filolisbac in High-Risk, Locally Advanced Cervical Cancer
Axalimogene Filolisbac in High-Risk, Locally Advanced Cervical Cancer’ AIM2CERV Phase 3 Study as Adjuvant Monotherapy to Prevent Recurrence in High-Risk Cervical Can Trial Desig} Eligibility HRLACC FIGO stage I-Il with positive pelvic nodes FIGO stage Ill- > IVA Any FIGO stage with para- aortic node
Slide 14: Combination of ADXS-PSA with Pembrolizumab in Late-Stage Prostate Cancer
IMMUNOTHERAPIES™ Oe Combination — of ADXS- PSA. on with Pembrolizumab in Late-Stage ~ © *:: Prostate Cancer a? ‘
Slide 15: Efficacy: Overall Survival - PSA Decline
Efficacy: Overall Survival — PSA Decline = 50% vs. PSA < 50% Decline Part B - in Combination with Pembrolizumab A snuNonieneeitsn In all treated patients, an improv vival was observed in patients with = jose <50% PSA declines. _ a Part A: PSA Drop <50% 2 9 779 352-119 = “ : $ he = ’ g "| be—- + +e P
Slide 16: Combination Therapy of ADXS-PSA with Pembrolizumab Study Results
Combination Therapy of ADXS-PSA with Pembrolizumab in Metastatic Castration- IMMUNOTHERAPIES. Resistant Prostate Cancer Study Results ‘+ Combination of ADXS-PSA and ) /¢ In the treated population, ‘+ The percentage of patients pembrolizumab appeared safe patients who received with PSA declines from
Slide 17: Neoantigen-Directed Programs: ADXS-NEO and ADXS-HOT
ADVAXIS IMMUNOTHERAPIES™ Neoantigen-Directed Programs: ADXS-NEO - Patient Specific ADXS-HOT - ‘Off the Shelf’
Slide 18: Why Neoantigens?
Why Neoantigens? iin noselanAr iis Vi 18 ‘Presented at AACR 2018 by Coder et al
Slide 19: Neoantigen Competitive Landscape: How We Measure Up
Neoantigen Competitive Landscape: How We Measure Up ADVAXIS Advaxis’ Lm platform + Antigen Targets: Directed against tumor-specific targets and engaging the patient’s immune system to destroy tumor cells. Select Companies in the Space: 19 NEON OTHER NEOANTIGEN APPROACHES? Limited clinical evidence a
Slide 20: ADXS-NEO
ADVAXIS IMMUNOTHERAPIES™ ADXS-NEO Patient-specific, neoantigen-directed therapies pee |: Ue (
Slide 21: ADXS-NEO: The Personalized Approach
ADXS-NEO: The Personalized Approach Activates a patient's immune system, creating a targeted T cell response to personal neoantigens based on unique, patient-specific mutations The Lm platform’s impact on the immune system (i.e., innate immunity, adaptive immunity, and changes to TME) provides poten
Slide 22: ADXS-NEO: Study Design
ADXS-NEO: Study Design ved * First patient dosed June 2018 Tumor Types: Endpoints: i Dose 7 + Metastatic - Prima microsatellite [Settled FEE ae Tolerabilit nee eiabiealon Expansion Phase y/ ry cancer n= 9-18 SeCOndatY, + Metastatic 3+3 design n=30 Clinical activity squamous 110°. 2 x10°. or (10 per
Slide 23: ADXS-HOT
ADVAXIS IMMUNOTHERAPIES™ ADXS-HOT Cancer-type specific, neoantigen-directed — , drug candidates O43
Slide 24: ADXS-HOT: Targeting Multiple OFAs, CTAs and Hotspots
24 DXS-HOT: Targeting Multiple OFAs, CTAs and Hotspots Increases Patient Applicability and Clinical Activity Potential Hotspot mutations have demonstrated pre-clinical activity in Advaxis’ Lm Technology" 1. Data on file, Advaxis, Inc. 2017. ADXS-HOT constructs target both public, or shared, hotspot
Slide 25: ADXS-HOT: Priority Tumor Types
ADXS-HOT: Priority Tumor Types e ADXS-503 for Non-small Cell Lung Cancer = IND allowed = First patient is anticipated soon e ADXS-504 for Prostate Cancer — IND anticipated in 2019 e ADXS-506 for Bladder Cancer — IND anticipated in 2019 First patient in ADXS-503 for NSCLC expected in early 2019 25
Slide 26: Corporate Information
ADVAXIS IMMUNOTHERAPIES™ Corporate Information
Slide 27: Anticipated Catalysts
Anticipated Catalysts ADVAXIS Over the Next 12-24 Months + Announce planned Investigator Sponsored Trial in Head and ADXS-HPV (axalimogene filolisbac) Neck Gancer Q1 2019 + Metastatic Prostate Ph1/2 Combination with pembrolizumab-- ADXS-PSA Part B Monotherapy Combination Therapy Data (12-mo PFS Q1 2
Slide 28: Executive Management Team
Executive Management Team ch Kenneth A. Berlin Molly Henderson Robert Petit Dr. Andres Gutierrez Chief Executive Officer Chief Financial Officer Chief Scientific Officer Chief Medical Officer ROSETTAGENOMICS™ TOVANCE, peste, PHARMACIA Gofmrenafofmren Yorersasesnes MGI. AESGEN Ortho wcoMousr(GormRS —
Slide 29: Financial Information, as of October 31, 2018
Financial Information, as of October 31, 2018 (fiscal year end) ¢ Cash on hand - $45.1 million = Reduced annual net cash burn to ~$50 million, from ~$80 million ¢ No debt e Shares outstanding: 69.6 million = Fully diluted shares outstanding: 89.2 million 29
Slide 30: Advaxis Overview
Advaxis Overview Creating Next-Generation Cancer Immunotherapies, Using a Proprietary Lm Platform Unique Lm Technology Platform: Enables broad and diverse pipeline of Phase 1 to Phase 3 programs across several tumor types Platform Validation: Demonstrated manageable safety profile along with clinica